Vertex Pharmaceuticals VRTX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.99B-6.4% | $3.19B+3.7% | $3.08B+3.8% | $2.96B+7.0% | $2.77B-4.9% | ||
| $392.8M-15.7% | $466M+12.3% | $414.8M+1.8% | $407.5M+12.3% | $363M-14.3% | ||
| $2.59B-4.8% | $2.72B+2.3% | $2.66B+4.1% | $2.56B+6.2% | $2.41B-3.3% | ||
| 86.8%+1.5pp | 85.4%-1.1pp | 86.5%+0.3pp | 86.3%-0.6pp | 86.9%+1.4pp | ||
| $493.7M+1.4% | $487M+9.4% | $445.1M+4.8% | $424.6M+7.1% | $396.4M+5.0% | ||
| —— | $48.68M0.0% | $48.68M0.0% | $48.68M0.0% | $48.68M+87.4% | ||
| $55.9M+0.4% | $55.7M+3.1% | $54M+4.4% | $51.7M+6.8% | $48.4M+4.1% | ||
| —— | $200K0.0% | $200K0.0% | $200K0.0% | $200K— | ||
| $1.85B-6.8% | $1.98B+5.0% | $1.89B+4.2% | $1.81B-15.3% | $2.14B+13.5% | ||
| $1.14B-5.6% | $1.21B+1.7% | $1.19B+3.0% | $1.15B+82.7% | $630.1M— | ||
| 38.1%+0.3pp | 37.8%-0.8pp | 38.6%-0.3pp | 38.8%+16.1pp | 22.7%— | ||
| $1.25B-5.9% | $1.33B+2.5% | $1.3B+1.2% | $1.28B+75.7% | $730.4M-35.7% | ||
| $221.5M+58.3% | $139.9M-35.2% | $215.9M-13.7% | $250.1M+197% | $84.1M-62.4% | ||
| $1.03B-13.4% | $1.19B+10.0% | $1.08B+4.8% | $1.03B+59.8% | $646.3M— | ||
| 34.5%-2.8pp | 37.3%+2.1pp | 35.2%+0.4pp | 34.8%+11.5pp | 23.3%— | ||
| $4.02-13.4% | $4.64+10.5% | $4.20+5.3% | $3.99+60.2% | $2.49— | ||
| $4.06-13.4% | $4.69+10.6% | $4.24+5.5% | $4.02+59.5% | $2.52— | ||
| 256.3M-0.7% | 258M+0.2% | 257.6M-0.5% | 258.9M-0.2% | 259.5M+0.6% | ||
| 254.1M-0.6% | 255.7M0.0% | 255.6M-0.4% | 256.7M-0.1% | 256.9M-0.4% | ||
| —— | $50.7M0.0% | $50.7M0.0% | $50.7M0.0% | $50.7M+137% | ||
| —— | $5.05M0.0% | $5.05M0.0% | $5.05M0.0% | $5.05M0.0% | ||
| —— | $7.8M0.0% | $7.8M0.0% | $7.8M0.0% | $7.8M+23.8% | ||
| —— | $0.250.0% | $0.250.0% | $0.250.0% | $0.25— | ||
| —— | $169.78M0.0% | $169.78M0.0% | $169.78M0.0% | $169.78M-3.7% | ||
| —— | $121.45M0.0% | $121.45M0.0% | $121.45M0.0% | $121.45M+56.8% | ||
| —— | $8.98M0.0% | $8.98M0.0% | $8.98M0.0% | $8.98M-69.6% | ||
| —— | -$131.75M0.0% | -$131.75M0.0% | -$131.75M0.0% | -$131.75M-20.1% | ||
| —— | $9.58M0.0% | $9.58M0.0% | $9.58M0.0% | $9.58M-72.4% | ||
| —— | -$127.7M0.0% | -$127.7M0.0% | -$127.7M0.0% | -$127.7M-46.4% | ||
| —— | -$5.53M0.0% | -$5.53M0.0% | -$5.53M0.0% | -$5.53M+54.6% | ||
| —— | $15.78M0.0% | $15.78M0.0% | $15.78M0.0% | $15.78M+20.7% | ||
| —— | 60%— | —— | —— | —— | ||
| —— | $38.95M0.0% | $38.95M0.0% | $38.95M0.0% | $38.95M-2.9% | ||
| —— | $0.050.0% | $0.050.0% | $0.050.0% | $0.050.0% | ||
| —— | $200K0.0% | $200K0.0% | $200K0.0% | $200K— | ||
| —— | -2.1%— | —— | —— | —— | ||
| —— | -$24.35M0.0% | -$24.35M0.0% | -$24.35M0.0% | -$24.35M— | ||
| —— | 0%— | —— | —— | —— | ||
| —— | -$15.38M0.0% | -$15.38M0.0% | -$15.38M0.0% | -$15.38M— | ||
| —— | -1.3%— | —— | —— | —— | ||
| —— | $14.63M0.0% | $14.63M0.0% | $14.63M0.0% | $14.63M— | ||
| —— | 1.3%— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $00.0% | $00.0% | $00.0% | $0— | ||
| —— | —— | —— | —— | —— | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| —— | 1.4%— | —— | —— | —— | ||
| —— | $1.8M0.0% | $1.8M0.0% | $1.8M0.0% | $1.8M-76.7% | ||
| —— | -$3.43M0.0% | -$3.43M0.0% | -$3.43M0.0% | -$3.43M+49.8% | ||
| —— | $705.3M0.0% | $705.3M0.0% | $705.3M0.0% | $705.3M+306% | ||
| —— | $455.5M0.0% | $455.5M0.0% | $455.5M0.0% | $455.5M+12.6% | ||
| —— | $242.23M0.0% | $242.23M0.0% | $242.23M0.0% | $242.23M— | ||
| —— | $18.55M0.0% | $18.55M0.0% | $18.55M0.0% | $18.55M— | ||
| —— | $243.78M0.0% | $243.78M0.0% | $243.78M0.0% | $243.78M— | ||
| —— | $6.35M0.0% | $6.35M0.0% | $6.35M0.0% | $6.35M— | ||
| —— | -$475K0.0% | -$475K0.0% | -$475K0.0% | -$475K— | ||
| —— | $16.08M0.0% | $16.08M0.0% | $16.08M0.0% | $16.08M— | ||
| —— | $38.6M0.0% | $38.6M0.0% | $38.6M0.0% | $38.6M— | ||
| —— | $15.48M0.0% | $15.48M0.0% | $15.48M0.0% | $15.48M— | ||
| $82.3M-78.9% | $389.4M-18.8% | $479.6M-6.6% | $513.3M+178% | $184.4M-32.2% | ||
| $35.6M-7.0% | $38.3M+208% | -$35.3M-564% | $7.6M-71.0% | $26.2M+212% | ||
| -$39.8M-140% | $99.4M+65.9% | $59.9M+226% | $18.4M-89.2% | $169.6M— | ||
| $70.5M+111% | -$664.5M-300% | $332.9M+99.8% | $166.6M+246% | $48.1M— | ||
| $97.7M+26.2% | $77.4M-41.0% | $131.1M-11.8% | $148.6M-11.1% | $167.1M+13.3% | ||
| $23.1M-78.2% | $105.8M+26.1% | $83.9M+233% | -$63.2M-387% | $22M— | ||
| -$173.4M-169% | $250.6M+513% | $40.9M-46.5% | $76.4M+172% | $28.1M-82.9% | ||
| $3.2M+6.7% | $3M-6.3% | $3.2M-8.6% | $3.5M+29.6% | $2.7M0.0% | ||
| $114.8M— | —— | —— | —— | $117.9M— | ||
| —— | $64.38M0.0% | $64.38M0.0% | $64.38M0.0% | $64.38M+27.5% | ||
| -$538.8M-598% | -$77.2M+93.3% | -$1.15B-231% | -$349.2M+48.7% | -$680.4M-73.9% | ||
| -$431.9M-49.9% | -$288.1M-146% | -$117M+75.9% | -$484.5M-768% | -$55.8M+93.2% | ||
| $1.43B+187% | $498M-59.9% | $1.24B+15.7% | $1.07B+31.0% | $818.9M+765% | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | $45.8M0.0% | $45.8M0.0% | $45.8M0.0% | $45.8M+61.4% | ||
| $5M+122% | -$23.1M— | $0+100% | -$57.8M-47.4% | -$39.2M-139% | ||
| $0— | —— | -$9.8M-174% | $13.2M+175% | -$17.6M-18.1% | ||
| $0-100% | $15.9M— | $0-100% | $4.3M-18.9% | $5.3M-82.8% | ||
| $336.9M+162% | $128.4M-88.0% | $1.07B+173% | $391.8M-8.0% | $426.1M+2.0% | ||
| $228.5M+9,040% | $2.5M-97.3% | $91M+1,442% | $5.9M-97.8% | $270.5M+3,605% | ||
| $2.51B+104% | $1.23B-8.5% | $1.35B-38.1% | $2.17B+31.9% | $1.65B-23.7% | ||
| $133.4M-10.7% | $149.4M+46.8% | $101.8M-30.1% | $145.7M+258% | $40.7M-56.0% | ||
| $27M-50.0% | $54M+584% | $7.9M-83.9% | $49.1M+194% | $16.7M-51.3% | ||
| -$400K-136% | $1.1M0.0% | $1.1M-45.0% | $2M+500% | -$500K-156% | ||
| $2.21B+102% | $1.09B-17.9% | $1.33B-27.7% | $1.84B+12.3% | $1.64B+12.1% | ||
| —— | $13.9M0.0% | $13.9M0.0% | $13.9M0.0% | $13.9M+11.2% | ||
| —— | -$26.88M0.0% | -$26.88M0.0% | -$26.88M0.0% | -$26.88M— | ||
| —— | $68.83M0.0% | $68.83M0.0% | $68.83M0.0% | $68.83M— | ||
| $961.6M-1.2% | $973.7M-0.4% | $977.7M-0.1% | $978.4M-0.1% | $979.7M-1.9% | ||
| $2.99B-6.4% | $3.19B+3.7% | $3.08B+3.8% | $2.96B+7.0% | $2.77B-4.9% | ||
| $166.4M+5.6% | $157.6M-19.1% | $194.9M+16.5% | $167.3M+0.7% | $166.1M-1.0% | ||
| —— | 7K— | —— | —— | —— | ||
| —— | $36.95M0.0% | $36.95M0.0% | $36.95M0.0% | $36.95M+31.0% | ||
| —— | $502.97— | —— | —— | —— | ||
| —— | $125.30— | —— | —— | —— | ||
| —— | 447K— | —— | —— | —— | ||
| —— | $1.2M0.0% | $1.2M0.0% | $1.2M0.0% | $1.2M+77.8% | ||
| —— | $1.43M0.0% | $1.43M0.0% | $1.43M0.0% | $1.43M+200% | ||
| —— | $1.58M0.0% | $1.58M0.0% | $1.58M0.0% | $1.58M-56.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | $34.63M0.0% | $34.63M0.0% | $34.63M0.0% | $34.63M+50.7% | ||
| —— | $3.28M0.0% | $3.28M0.0% | $3.28M0.0% | $3.28M+132% | ||
| —— | -$1.85M0.0% | -$1.85M0.0% | -$1.85M0.0% | -$1.85M-563% | ||
| —— | $10.98M0.0% | $10.98M0.0% | $10.98M0.0% | $10.98M— | ||
| —— | $29.88M0.0% | $29.88M0.0% | $29.88M0.0% | $29.88M+0.3% | ||
| —— | $1.3M0.0% | $1.3M0.0% | $1.3M0.0% | $1.3M+13.0% | ||
| —— | $36.48M0.0% | $36.48M0.0% | $36.48M0.0% | $36.48M+61.6% | ||
| —— | $2.68M0.0% | $2.68M0.0% | $2.68M0.0% | $2.68M-35.5% | ||
| —— | $12.53M0.0% | $12.53M0.0% | $12.53M0.0% | $12.53M+14.9% | ||
| $1.14B-5.6% | $1.21B+1.7% | $1.19B+3.0% | $1.15B+82.7% | $630.1M-44.7% | ||
| $1.19B-5.4% | $1.26B+1.7% | $1.24B+3.1% | $1.2B+77.3% | $678.5M-42.8% | ||
| $1.19B-5.4% | $1.26B+1.7% | $1.24B+3.1% | $1.2B+77.3% | $678.5M-42.8% | ||
| 40%+0.4pp | 39.5%-0.8pp | 40.3%-0.3pp | 40.6%+16.1pp | 24.5%-16.2pp | ||
| $1.14B-5.6% | $1.21B+1.7% | $1.19B+3.0% | $1.15B+82.7% | $630.1M-44.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Vertex Pharmaceuticals's revenue?
- Vertex Pharmaceuticals (VRTX) generated $12.2B in revenue over the trailing twelve months, up 10.1% year over year.
- Is Vertex Pharmaceuticals profitable?
- Vertex Pharmaceuticals reported $4.3B in net income over the trailing twelve months, a 35.5% net margin.
- What are Vertex Pharmaceuticals's profit margins?
- Gross margin is 86.2% and operating margin is 38.3%, with a 35.5% net margin.
- What is Vertex Pharmaceuticals's earnings per share?
- Vertex Pharmaceuticals's diluted EPS over the trailing twelve months is $16.85.
- Where does Vertex Pharmaceuticals's income statement data come from?
- Every line is extracted from Vertex Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
